×

RNS Number : 5992V

Oxford Pharmascience Group PLC

19 April 2016

 

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience Announces Positive Regulatory Advice from MHRA on OXPzeroTM NSAIDs programme

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, announces that it has received clear and positive feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) on the UK regulatory pathway to obtain marketing authorisation for OXPzeroTM Ibuprofen. 

The Company currently has OXPzeroTM variants of two non-steroidal anti-inflammatory drug (NSAID) molecules in clinical development, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen.  These leverage the company's proprietary technology platform which aims to mask the bitter taste and irritation of NSAIDs and to provide reduced risk of gastrointestinal (GI) side effects.  Ibuprofen and naproxen are the two dominant NSAID molecules in the pain relief and anti-inflammatory sector, with combined worldwide sales in excess of $5bn per annum.(1)  The Company is in ongoing partnering discussions relating to its OXPzeroTM assets.

The recently received feedback follows a scientific advice meeting with the MHRA in early March on the development programme for OXPzeroTM Ibuprofen.  Specific key elements of the MHRA feedback received are:

·    OXPzeroTM Ibuprofen can be classified as a new salt form of Ibuprofen, not a new active substance or combination product, which greatly simplifies the regulatory pathway

·    The phase III study protocol for the product registration application with improved GI safety claim has been clarified

Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience, commented:

"We are very pleased with the outcome of this meeting. The MHRA's feedback has provided clear direction for the pivotal studies required to gain approval of marketing authorisation for OXPzeroTM Ibuprofen.  This gives us a clear understanding of the timelines and associated investment required. We believe this puts us in a strong position as we continue with our partnering discussion process for both OXPzeroTM Ibuprofen and Naproxen."

 

Further information

The Company has obtained confirmation from the MHRA that OXPzeroTM Ibuprofen can be classified as a new salt form of ibuprofen and not a new active substance or combination product which greatly simplifies the regulatory pathway.  During this meeting only OXPzeroTM Ibuprofen was discussed, however, it is the Company's opinion that the MHRA feedback received is equally applicable to OXPzeroTM Naproxen and to OXPzeroTM NSAIDs in general.  Following this scientific advice meeting, the Company can confirm that the MHRA has provided guidance on its requirements for the pivotal development programme of OXPzeroTM Ibuprofen. The most appropriate legal basis of application for the over-the-counter and prescription strength product marketing authorisation applications was also confirmed – bioequivalent products will follow the 10(3) route, while non-bioequivalent products will follow the 8(3) route and require an additional single dose, dental pain study to prove the efficacy of OXPzeroTM Ibuprofen.

OXPzeroTM Ibuprofen and OXPzeroTM Naproxen compounds have been shown to deliver a range of key benefits that can be leveraged across multiple differentiated product applications.  Specifically, by comparison with generic NSAIDs, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen:

·    are milder in the GI tract, delivering major reduction in severe GI mucosal damage;

·    significantly mask the bitter taste/burn associated with NSAIDs; and

·    deliver an attractive PK profile with adaptable drug release properties.

 

NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day.(1)

 

For further information:

Oxford Pharmascience Group Plc   

Marcelo Bravo, Chief Executive          +44 20 7554 5875

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer                 +44 20 7496 3000

 

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take.  The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance.  By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGUGDSIBBBGLC

Close

×

RNS Number : 4486V

Epistem Holdings plc

18 April 2016

 

RNS Press Release

For release: 18 April 2016

 

Epistem Begins Full Commercial Launch for Genedrive® Tuberculosis Tests in India

 

Genedrive® Enables Early Detection of TB and Antibiotic Resistance Without Need for Central Laboratory Facilities

 

 

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that alongside its Indian commercialisation partner, Xcelris Labs, the Company has begun the full commercial launch for its Genedrive® tuberculosis (TB) and antibiotic resistance test.

 

Xcelris Labs, one of India's leading genomics products and services testing companies, initially intends to target Genedrive® at the country's approximately 5,000 private clinical laboratories to provide rapid point-of-care molecular identification and antibiotic resistance/drug susceptibility testing for TB. This accepted PCR based molecular diagnostic technique has generally only been available through selected large hospital central laboratory settings. Genedrive®'s low system cost, ease of use and robustness has the potential to greatly increase the wider adoption and availablility of sophisticated molecular diagnostic analysis and consequently patients' access to testing in India.

 

David Budd, CEO of Epistem, commented "Full commercial TB launch in India is an important next step in the commercialisation of Genedrive®. For the majority of patients who cannot access large reference hospitals and clinics, TB testing in India currently relies on conventional technologies such as microscopy and cell culture to detect infection and determine the most appropriate treatment. Genedrive® offers the ability to detect infection and antibiotic resistance in hours rather than days with important implications for more immediate and effective treatment, and the prevention of  spread of infection. The target pricing of Genedrive® and TB test cartridges makes our product an attractive commercial and clinical alternative to traditional diagnostic techniques."

 

Milina Bose, Executive Director and Vice President of Xcelris said "There are more than 30 million smear microscopy tests conducted in India a year with many carried out in smaller and medium sized private laboratories. Our commercial teams are very excited to now be commercialising Genedrive® and will initally be marketing the system and assays to laboratories outside of the traditional public facilities where molecular TB testing now occurs. We believe that providing these laboratories with the ability to carry out molecular testing with Genedrive® will be very attractive to them and impact positively on patient treatment options in India."

 

 

 

– Ends –

 

For further details please contact:

Epistem Holdings Plc

David Budd: CEO                                                                                                      +44 (0)161 606 7258

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel                                                                                                              +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                           +44 (0)203 709 5700

Matthew Neal

epistem@consilium-comms.com 

 

Notes to Editors

 

About TB

Tuberculosis is the largest single infectious cause of death among young people and adults today and accounts for one quarter of all preventable adult deaths in developing countries. There were 9.6m new cases in 2014. TB can be treated with antibiotics with an 80% success rate but conventional diagnosis for TB is time consuming reliant on older tools. New molecular test approaches are the fastest growing segment in TB testing but existing technologies are not designed to reach out of large hospitals to smaller laboratories where most tests are currently run. Genedrive®'s low cost, speed-to-result, small size and robustness has the potential to extend access to sophisticated molecular testing outside a centralised laboratory setting.

 

About Epistem

Epistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com

 

About Xcelris

Xcelris Genomics is part of the global Abellon business group with interests in diverse areas including clean energy, agrisciences, and genomics, as well as various initiatives in education and social development. Throughout India, Xcelris is a leading company in Genomics products and services and is  providing diagnostic testing services in the specialised field of Medical Genetics and Nutrigenomics.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

PRLIRMBTMBABTTF

Close

×

RNS Number : 2831V

Vela Technologies PLC

15 April 2016

 

15 April 2016

Vela Technologies plc

("Vela" or the "Company")

 

Completion of investment in Portr Limited

 

Further to the announcement of 8 March 2016 the Board of Vela (AIM: VELA), the investing company focused on early stage and pre-IPO disruptive technology investments, is pleased to announce that Vela has completed its investment of £151,343 in Portr Limited ("Portr"), the owner of the on-demand airport luggage transfer service, AirPortr. The funds were paid by Vela to Portr in early April 2016.  

Vela has been informed by Portr that they have now successfully completed their fundraising exercise with existing shareholders to raise £3 million (the "Portr Fundraising").

Following completion of the investment Vela has an interest in 101,989 shares in Portr which represents 3.9% of Portr's issued share capital following completion of the Portr Fundraising. Vela's enlarged shareholding in Portr is valued at £1.079 million, based on the price of the Portr Fundraising. Following the investment of £151,343 in the Portr Fundraising, Vela has invested a total of £251,343 in cash in Portr over three funding rounds.

Further details on Portr and the background to the investment are contained in the announcement of 8 March 2016.

For further information please contact:

Vela Technologies plc
Brent Fitzpatrick, Non-Executive Chairman Antony Laiker, Director		Tel: +44 (0) 7802 262 443
Allenby Capital Limited (Nominated Adviser)
Nick Athanas/Katrina Perez/James Reeve		Tel: +44 (0) 20 3328 5656
Smaller Company Capital Limited (Broker) Rupert Williams/Jeremy Woodgate	Tel: +44 (0) 20 3651 2910

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGGUQWCUPQGMC

Close

×

Neville Registrars is delighted to welcome Osirium Technologies plc as the newest addtion to its list of client companies.

The Osirium team have intelligently combined the latest generation of Cyber-Security and Automation technology to create the world’s first, built-for-purpose, Privileged Protection and Task Automation solution for the Hybrid-Cloud world.

Further information can be found on the Company's website: https://osirium.com/

Close

×

RNS Number : 2600V

Flowgroup plc

14 April 2016

 

 

Flowgroup plc

("Flowgroup" or the "Company")

 

First commercial installations of Flow boiler now complete

 

Flowgroup plc (AIM: FLOW), which provides innovative energy technologies, energy supply and energy services, announces that the first commercial installs of the Flow boiler in customer homes have been completed. 

 

These new customer installs were completed on time and to plan. The installed Flow boilers are performing in line with expectations, both heating the home and generating electricity.

 

As previously announced, the Company will now continue with installations, ramping up over the next six months and aiming for higher volume sales in the winter months.

 

A blog post with photos of an install is available at: http://www.flowenergy.uk.com/blog/flow-boiler/flow-boiler-first-installs/

 

Tony Stiff, Chief Executive Officer of Flowgroup, commented: "We are very pleased to announce that we have completed the first commercial customer installations of the Flow boiler which are providing both heat and power. Initial customer satisfaction is high and the Flow Brand Ambassadors involved in the first installs are excited to be involved in making history by installing a real world's first – an affordable, electricity-generating boiler. We will continue with installations through the summer before ramping up to higher volume in the key winter period. I'd like to thank every member of our team for the effort they have put in to bring us to this historic moment."   

 

Flowgroup plc		www.flowgroup.uk.com
Tony Stiff, Chief Executive Officer, Flowgroup plc		Tel: +44 (0)20 3137 4525
Walbrook PR Ltd	Tel: +44 (0)20 7933 8780 or flowgroup@walbrookpr.com
Paul McManus (Media Relations)			Mob: 07980 541 893

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEALLLFFKKEFF

Close

×

RNS Number : 7173U

Midatech Pharma PLC

11 April 2016

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech's Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US

 

–  Midatech further expands its commercial footprint in US, supporting the Zuplenz® launch

 

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces its forthcoming full commercial launch of Zuplenz® (ondansetron) Oral Soluble Film to prevent post-operative, chemotherapy and radiation-induced nausea and vomiting, in the United States.

 

In support of the Zuplenz product launch and Midatech's growing oncology supportive care portfolio, Midatech has invested in a significant expansion of its commercial organization, including additional field sales representation, field sales management, national accounts personnel, and marketing and internal support staff. Midatech's newly expanded commercial team will attend the Zuplenz launch meeting Tuesday to Friday of this week in Dallas, Texas.

 

Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "Zuplenz is a valuable treatment option that offers convenient relief from one of the most debilitating side-effects of common cancer treatments. The product launch of Zuplenz represents yet another step forward for Midatech and further leverages our commercial infrastructure in the US. Zuplenz is a perfect example of our rapidly growing portfolio of marketed oncology products and will further contribute to our growing revenue stream."

 

Zuplenz, acquired into Midatech's portfolio of marketed oncology products in December 2015, is a 5HT3 receptor antagonist. The novel oral soluble film technology used by Zuplenz offers an innovative approach to ondansetron delivery that, in comparison to other delivery methods, provides several key cancer patient benefits including a non-gritty delivery mechanism, non-patch delivery, discreet on-the-go usage, removal of the burden of swallowing pills during emesis, and no sedative side effects.

 

Jerilyn Arnold, Senior RN, Oncology Nurse Specialist at Texas Oncology, said: "In practice, patients often find non-tablet therapies for CINV and RINV sub-optimal due to gritty residue, potential need for the patient to wear a patch and possible exacerbation of their nausea and vomiting due to various other product characteristics. Together, these limitations contribute to reduced compliance and efficacy often leading to various morbidities associated with CINV and RINV. Zuplenz provides an excellent localised therapy solution for the treatment of both CINV and RINV because the novel formulation avoids the pitfalls that come with other ondansetron products."

 

According to data from Symphony Health Solutions, there were approximately twenty million prescriptions written in 2015 in the US for ondansetron, with more than half of the ondansetron market being fulfilled with oral dissolving tablets. Zuplenz's unique profile and benefits, combined with both excellent commercial reimbursement and Midatech Pharma's zero-dollar out-of-pocket patient co-pay program (for qualifying individuals) provides a strong and proven platform to launch Zuplenz® into the US market.

 

David Benharris, MTPUS President, said: "We are very excited to add a unique and proven CINV/RINV product to our oncology supportive care portfolio. The planned growth of our commercial organisation in support of the Zuplenz launch allows us to add significant share of voice amongst the leading writers of oncology supportive care products, while further strengthening and expanding upon our relationships in these important offices."

 

Note to investors

Midatech will issue its 2015 Full Year Results on Wednesday 13 April 2016. Dr Jim Phillips, Chief Executive Officer, and Nick Robbins-Cherry, Chief Financial Officer, will host a call and a live Q&A session for analysts and investors at 1300 BST / 0800 EDT.

 

– ENDS –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie / Duncan Monteith

Corporate Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

RBC Europe Limited (Joint Broker)

Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman

Tel: +44 (0)207 653 4000

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

About Zuplenz® (ondansetron) Oral Soluble Film

Zuplenz® (ondansetron) Oral Soluble Film was acquired by Midatech Pharma (AIM: MTPH; Nasdaq: MTP) from Galena Biopharma, Inc. (Nasdaq: GALE) in December 2015. The product is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. Zuplenz uses MonoSol's proprietary PharmFilm® technology, an oral soluble film that dissolves on the tongue in less than 30 seconds, thereby eliminating the burden of swallowing pills during periods of emesis. The active pharmaceutical ingredient in Zuplenz®, ondansetron, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.  Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.  Discontinue using Zuplenz at the first sign of hypersensitivity. For more information and full prescribing information on Zuplenz, please visit www.zuplenz.com.

 

Forward-Looking Statement

 

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the anticipated medical benefits of Zuplenz, our expected revenues, market and growth opportunities and other benefits associated Zuplenz® and other statements that are not historical fact. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

PRLGGUWUCUPQPGU

Close

×

RNS Number : 8032S

Fitbug Holdings PLC

22 March 2016

 

Fitbug Holdings Plc / Epic: FITB.L / Index: AIM / Sector: Leisure

22 March 2016

FITBUG HOLDINGS PLC ('FITBUG' OR 'THE COMPANY')

SUCCESSFUL CUSTOMER ROLLOUT WITH STRATEGIC PARTNER PUNTER SOUTHALL

 

Fitbug Holdings, the AIM quoted technology developer and digital wellness pioneer, is pleased to announce the success of an initial phase with the Company's strategic partner Punter Southall Health & Protection. Between November 2015 and February 2016 Punter Southall Health & Protection rolled out Fitbug's innovative Digital Wellness Solution to four of its clients.  Fitbug and Punter Southall Health & Protection will now look to strengthen their strategic relationship and accelerate the promotion of the offering to more of Punter Southall Health & Protection's client base.

 

Punter Southall Health & Protection is one of the strongest and most innovative health and protection advisers in the UK with 750 corporate clients, 2,700 SME's and 4,500 personal customers. The progression of its relationship with Fitbug confirms the Company's strategy to focus on a B2B digital wellness offering designed to increase employee productivity, wellbeing and engagement through targeted health and wellness programmes.

 

The Directors believe that the success of the initial trial demonstrates the potential opportunity for Fitbug's Digital Wellness Solution, which offers a holistic and preventative approach to wellness as part of a cost-effective corporate wellness package. The package comprises personalised mobile coaching, gamification, and management reporting.  Fitbug's wellness package is focused not only on improving health, but overall wellbeing through mobile technology, with particular emphasis on stress, sleep, nutrition and activity.

 

Fitbug CEO Anna Gudmundson said "Over the last 10 years Fitbug has built a strong technology platform, gathered valuable data, and has learnt how to engage both corporate and individual users to create lifestyle changes. We are now using our technology and expertise in our clear focus on the needs of the B2B market in order to capitalise on what we believe could be a significant commercial opportunity.

 

"Punter Southall Health & Protection is focused on helping clients control costs and improving the health and wellbeing of their employees, and is finding innovative ways to add ROI to their clients.  The missions of both companies are very much aligned. Together the Fitbug and Punter Southall Health & Protection proposition provides excellent value to corporate clients and offers Fitbug an accelerated route to market, fulfilling the Company's strategy to access the B2B market not only directly, through agreements with mid-large corporations, but also via strategic partnerships with insurance brokers / health insurers. We are very excited to grow our relationship with Punter Southall Health & Protection, who are pioneering their industry."

 

John Dean Managing Director of Punter Southall Health & Protection said, "We are looking forward to expanding our partnership with Fitbug, which has been an innovator in digital wellness.  We are increasingly seeing employers implementing wellness initiatives, which help staff to improve their wellbeing and adopt healthier behaviours. This in turn improves the performance of their insurance policies. Given both Fitbug and Punter Southall Health & Protection's expertise in our respective sectors, this proposition is a complimentary fit, and will provide our corporate clients with a unique, innovative and highly personalised health and wellbeing solution."

 

 

**ENDS**

 

For further information visit www.kiqplan.com or www.fitbugholdings.com contact:

 

 

Anna Gudmundson / Donald Stewart	Fitbug Holdings Plc	020 7449 1000
Catherine Leftley / Marc Milmo	Cantor Fitzgerald Europe, Nomad and Joint Broker	020 7894 7000
Claire Louise Noyce / William Lynne / Niall Pearson	Hybridan LLP, Joint Broker	020 3764 2341
Elisabeth Cowell / Charlotte Heap	St Brides Partners Ltd, Public Relations	020 7236 1177

 

 

Notes

About Fitbug®

Fitbug is a leading provider of online health and well-being services which is pioneering an innovative 'Digital Wellness' model to help individuals to improve their lifestyles by making realistic changes to their daily routine. It combines activity tracking devices, which provide an understanding of each user's daily activity achievements, with mobile and web technology, which provides users with personalised weekly activity and nutrition targets, feedback, advice and encouragement to achieve "wellness".  This is centred on four key areas: stress, sleep, nutrition and activity.

 

Its "Kiqplan"TM digital health coaching platform is designed to make wearable technology relevant to new audiences and take the "so what?" out of activity tracking by providing structured action plans to help people achieve their wellness goals.

 

The Company is primarily focussed on the B2B market, mainly mid-to-large cap corporations and insurance brokers / health insurers, where significant growth opportunities have been identified, particularly in the UK and US.  An important part of the Company's focus is on building strategic relationships with organisations, which can integrate Fitbug or Kiqplan into their own service/product offerings or resell to their customer base.  For more information, visit www.fitbug.com and www.kiqplan.com.

 

About Punter Southall Health & Protection Background Information

Punter Southall Health & Protection – www.pshp.co.uk – has grown considerably since its launch in 2010 to become one of the most innovative and strongest health, protection and wellness advisers in the UK.

 

It acquired Enrich Reward Limited, the employee benefits consultancy in 2013, and The Private Health Partnership (PHP), the well-established health group with a 25 year successful history, incorporating RedArc and Medical Care Direct, in July 2014.

 

The company has over 160 employees split over three UK sites in Redhill, Surrey, central London and Baildon, Yorkshire. Recent milestones include:

 

•           February 2013: launch of Gladis, a unique online self-service platform used by companies to reduce the widespread risk and cost issues of managing protection insurances for their employees.

 

•           July 2014: launch of Healthsmart, a service that integrates occupational health, absence management and employee benefits to get employees back to work as soon as possible.

 

•           October 2014: Began distributing Havensrock, unique group life assurance products with bespoke solutions for the professional services sector and pension trustees.

 

•           April 2015: Launch of Havensrock Income Protection, which for the first time joined wellness and group income protection in the same product.

 

Punter Southall Health & Protection is a subsidiary of Punter Southall Group, one of the biggest, independently owned entities of its kind in the UK. The group provides actuarial advice, pensions' consultancy, administration, risk consultancy, employee benefits, investment services, and healthcare for pension scheme trustees, employers, private clients, Lloyd's insurers and institutions.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCEAKDFAALKEFF

Close

×

RNS Number : 6988S

Epistem Holdings plc

21 March 2016

 

RNS Press Release

For release: 21 March 2016

 

Award of Funding for Next Stage of US Department of Defense Programme

 to Develop Genedrive® Biohazard Identification Tests

 

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that the US Department of Defense has awarded $2.9m in funding for the next phase of Epistem's programme to develop a handheld Genedrive® test for biohazard identification.

 

In August 2015, Epistem announced the first $2.4m phase of the $7.8m programme with the US Department of Defense for the development and manufacture of Genedrive® as a biohazard identification system. The second phase announced today was triggered by successful progress to date and is expected to be largely undertaken during the financial year 2016/17.

 

David Budd, CEO of Epistem, commented "Today's announcement is a recognition of our team's expertise in developing new assays and marks a further important validation of Genedrive®'s potential  as a highly versatile molecular diagnostic system which can be used outside a central lab setting. The US Department of Defense programme funding increases our overall development capability and our ability to develop Genedrive® to realise its full potential."

 

 

– Ends –

 

For further details please contact:

Epistem Holdings Plc

David Budd: CEO                                                                                                           +44 (0)161 606 7258

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel                                                                                                                      +44 (0)207 418 8900

Tom Burt

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Laura Thornton                                                                         

epistem@consilium-comms.com 

 

 

Notes to Editors

 

Epistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCSESSWFFMSELD

Close

×

RNS Number : 8098S

ADVFN PLC

21 March 2016

 

21 March 2016

ADVFN PLC

Agreement with businessagent.com

ADVFN (LSE:AFN) is pleased to announce that it has signed an agreement with crowdfunding aggregator, Business Agent Limited ("businessagent.com") (the "Agreement").  

Pursuant to the Agreement, ADVFN has agreed to introduce businessagent.com  to its users and customers, by providing an exclusive listing on its website and mobile applications for equity and debt crowdfunding aggregation.

businessagent.com will initially spend £15,000 on advertising with ADVFN, but if it raises £2 million in funding, it has committed to spend another £60,000 in advertising. In consideration for this, ADVFN has been granted a 4 per cent. shareholding in businessagent.com, worth £120,000 at the current indicative equity valuation for businessagent.com of £3 million. The agreement is for a minimum of 3 years and shall continue on a month by month basis thereafter.

ADVFN will create a link to businessagent.com on the home page navigation of each of its websites. This will start in the UK, but it is envisaged that as crowdfunding becomes more established amongst ADVFN's overseas territories businessagent.com's services will be extended to those territories as well.

Clem Chambers, CEO of ADVFN said "Crowdfunding is still a new sector and one with great potential, quality is much better than quantity. businessagent.com brings the whole sector into one place".

Sacha Bright, CEO of businessagent.com said " this agreement not only catapults businessagent.com several years into the future in terms of traffic and users, but it is also a climactic event for crowdfunding. ADVFN's  users invest regularly in the main financial markets and this is an opportunity to introduce professional high net worth individuals to equity & debt crowdfunding. The market up to this point has been grown by word of mouth from the high net worth retail investor.

Notes to Editors

businessagent.com lists every equity crowdfunded investment opportunity it can find and collates data on loan based crowdfunding thus enabling visitors to identify lending and investment opportunities all in one place. businessagent.com is also able to introduce companies to alternative loan providers and equity crowdfunding sites to raise capital for their businesses.

businessagent.com has a vision of creating the primary alternative finance market place through aggregation. Its mission is to help businesses get the funding they need and help investors improve their returns from their crowdfunding investments by allowing them to compare investments, see all the opportunities in one place and access data on the whole market so that they can make more informed decisions.

businessagent.com was founded in December 2013 and launched in July 2014. It received its FCA authorisation in September 2015. For the year ended 31 December 2015 businessagent.com made a loss of £164,331.

 

– ends –

Contacts:

Clem Chambers: clemc@advfn.com

Salmaan Khawaja / Jen Clarke / Jamie Barklem: 0207 383 5100

Grant Thornton UK LLP (Nominated Adviser)

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRUAABRNNAOUAR

Close

×

Neville Registrars is delighted to welcome Hygea VCT PLC as the newest addtion to its list of client companies.

Hygea VCT provides investors with access to a diversified portfolio of emerging and established MedTech companies qualifying for investment by a VCT.

Further information can be found on the Company's website: http://www.hygeavct.com/

Close